Fernand Desjarlais discusses the impact of the US Biosecure Act on the Life Science market. Approved by the US House Committee for Oversight and Accountability, the Act seeks to enhance national security by restricting US federal funding to entities engaged with certain foreign biotechnology companies. Read more below: https://lnkd.in/etXr_J25 #lifesciences #biosecureact #chinesebiotech
Mantell Associates
Executive Search Services
City of London, England 76,857 followers
Multidiscipline Global Life Science and Pharmaceutical Headhunting Firm.
About us
Mantell Associates is a multi-discipline headhunting firm focused on providing both permanent and contract recruitment services globally, to the Biotech, Pharmaceutical, CDMO, CRO, Diagnostics, Animal Health, Consulting, Medical Device and MedTech sectors. With success ranging across C-Suite, Commercial, Technical Operations, Scientific, Clinical, Quality and Regulatory, we pride ourselves on our ability to bring the top talent to our clients, and the best opportunities to the top talent. Our services span across our Partnership Service, Contingency, Project Management and Contract models, meaning that we can cater to our client’s every requirement.
- Website
-
www.mantellassociates.com
External link for Mantell Associates
- Industry
- Executive Search Services
- Company size
- 51-200 employees
- Headquarters
- City of London, England
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Contract Development Manufacturing Organisations, Contract Manufacturing Organisations, Preclinical, Active Pharmaceutical Ingredients, Cell & Gene Therapy, Finished Dosage Forms, Biologics, Toxicology, Pharmacology, Oncology, CDMO, CMO, Biomarkers, Vaccines, Contract Research Organisation, Clinical Trial Supplies, Bioanalytics, Bioanalysis, Fine Chemicals, and Highly Potent Active Pharmaceutical Ingredients
Locations
-
Primary
150 Minories
City of London, England EC3N 1LS, GB
-
2 S Biscayne Blvd
Miami, Florida 33131, US
-
Rigistrasse 3
Zug, 6300, CH
Employees at Mantell Associates
Updates
-
Corden Pharma - A Full-Service CDMO has committed to spend €900 million ($981 million) over the next 3 years to grow its Peptide technology platform. Read more below: https://lnkd.in/gpgsiJ-3 #peptides #pharmanews #investmentnews
CordenPharma to Invest ~€900M to Grow Its Peptide Technology Platform
contractpharma.com
-
Mantell Associates reposted this
MA Summer Party 2024 🥂 Our UK team celebrated a great first half of the year at the new Florattica Rooftop in London. An amazing afternoon with the best team in the sunshine! 4 years working alongside Alessandro Mantell and I've seen the company grow, adapt and change so much since 2020. We have an amazing team across London and Miami, and it never gets old to be part of a company as supportive, driven, collaborative and fun as Mantell Associates. Here's to the rest of 2024! #recruitmentlondon #recruitmentmarketing #summerparty
-
-
This week we welcomed Georgia Read to the MA London team! Georgia joins us as a Senior Associate, and will be specialising in the Commercial space across Europe. She brings two and half years experience recruiting in the EU within the Life Sciences market, and we look forward to her impact here at Mantell Associates. Welcome! #recruitmentlondon #welcome #lifesciencerecruitment
-
-
While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note from Morgan Stanley. Read more below: https://lnkd.in/gN7jMDHT #mergers #acquisitions #bigpharma
Amgen, BMS and Merck have the most exposure as Big Pharma eyes $183B patent cliff: analyst
fiercepharma.com
-
Lantheus is expanding its holdings of PET imaging agents for Alzheimer’s disease, with the acquisition of Meilleur Technologies. The deal grants Lantheus exclusive worldwide rights to Meilleur’s radiopharmaceutical diagnostic that highlights beta amyloid plaques in the brain. The injectable agent is currently in phase 3 development. Read more below: https://lnkd.in/eBU-c58q #acquisition #medtech #medtechnews
Lantheus acquires Alzheimer’s PET diagnostic developer Meilleur Technologies
fiercebiotech.com
-
Listen to what our clients and candidates have said about us... "Huseyin was a pleasure to work with while he placed me in my current position. He negotiated a deal that allowed my family and I to move across the country." Get in touch with Huseyin Pulat on +44 (0)20 3854 7700. #testimonialtuesday #pharmarecruitment #lifesciencerecruitment
-
-
Merck, known as MSD outside of the USA and Canada, has completed the previously announced acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of Merck. Read more below: https://lnkd.in/et7R6xCS #acquisition #biotech #biotechnews
Merck Completes Acquisition of EyeBio
contractpharma.com
-
Pfizer has dragged the oral GLP-1 candidate danuglipron back from the brink. Months after dropping one version of the asset, the Big Pharma has vowed to advance a once-daily, modified-release formulation on the strength of “encouraging pharmacokinetic data.” Read more below: https://lnkd.in/e94nSPKC #obesitydrugs #drugdevelopment #drugtrials
Pfizer bounces back in obesity, moving once-daily oral drug toward pivotal trials after earlier missteps
fiercebiotech.com
-
Thermo Fisher Scientific announced on 10 July that it has completed its acquisition of Olink Proteomics, a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. https://lnkd.in/e2WWGRsP #acquisition #proteomics #lifesciences
Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period
ir.thermofisher.com